tirzepatide cardiovascular outcomes 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major events (12.2% vs 13.1%; HR 0.92). What Tirzepatide and Cardiovascular Outcomes in

However, it can disrupt your menstrual cycle, potentially leading to confusion about your pregnancy status

#PsoriaticArthritis #GLP1 #Dermatology #Rheumatology #MedicalResearch GLP-1 therapy shows promise in psoriatic arthritis treatment A major new clinical trial is putting a spotlight on one of the biggest conversations in medicine right now: what happens when GLP-1based therapy is brought into psoriatic arthritis care

doi: 10.1111/bcp.13877 178 StockwellBRFriedmann AngeliJPBayirHBushAIConradMDixonSJet al

It is a GLP-1 receptor agonist , a medication that works by binding to GLP-1 receptors in the body

We recommend you book a consultation with us today to determine which treatment is best suited for you

CrossRef Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation Abdelkrim Khadir, Sina Kavalakatt, Dhanya Madhu, Maha Hammad, Sriraman Devarajan, Jaakko Tuomilehto, Ali Tiss Lipids in Health and Disease.2018;[Epub] CrossRef Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study Kyung Mook Choi, Kyungdo Han, Sanghyun Park, Hye Soo Chung, Nam Hoon Kim, Hye Jin Yoo, Ji-A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Yong Gyu Park, Seon Mee Kim Scientific Reports.2018;[Epub] CrossRef Obesity and Male Infertility: Role of Fatty Acids in the Modulation of Sperm Energetic Metabolism Alessandra Ferramosca, Mariangela Di Giacomo, Natalina Moscatelli, Vincenzo Zara European Journal of Lipid Science and Technology.2018;[Epub] CrossRef The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies F